Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CC-1 |
Synonyms | |
Therapy Description |
CC-1 is a bispecific antibody that targets both prostate specific membrane antigen (PSMA) and CD3, potentially resulting in antitumor activity (Cancer Res 2022;82(12_Suppl):Abstract nr CT141). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CC-1 | CC1|CC 1 | CD3 Antibody 99 PSMA Antibody 20 | CC-1 is a bispecific antibody that targets both prostate specific membrane antigen (PSMA) and CD3, potentially resulting in antitumor activity (Cancer Res 2022;82(12_Suppl):Abstract nr CT141). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05646550 | Phase I | CC-1 | Antibody CC-1 in Men With Biochemical Recurrence of Prostate Cancer (ProSperACC-1) | Recruiting | DEU | 0 |